Late-onset cholestatic hepatitis induced by olanzapine in a patient with schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 8, 2009, Pages 1574-1575

  Hung, Chung Chieh ^a   Wei, I Hua ^b   Huang, Chih Chia ^a,b  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BIPERIDEN; CLONAZEPAM; FLUOXETINE; FLUPENTIXOL; HALOPERIDOL; LITHIUM; MULTIVITAMIN; OLANZAPINE; PARACETAMOL; QUETIAPINE; RISPERIDONE; SULFINPYRAZONE; VALSARTAN; VITAMIN D;

ADULT; ANOREXIA; APPETITE DISORDER; ARTHRALGIA; AUDITORY HALLUCINATION; BRADYKINESIA; CASE REPORT; CHOLESTATIC HEPATITIS; DELUSION; DEPRESSIVE PSYCHOSIS; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG FEVER; DRUG WITHDRAWAL; EOSINOPHILIA; ESSENTIAL HYPERTENSION; FEMALE; GOUT; HOSPITAL ADMISSION; HUMAN; JAUNDICE; LETTER; LEUKOPENIA; MALAISE; MENTAL PATIENT; NAUSEA; PERSECUTORY DELUSION; PRESCRIPTION; PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; UPPER ABDOMINAL PAIN; VOMITING; WEAKNESS;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHOLESTASIS; FEMALE; HUMANS; MIDDLE AGED; SCHIZOPHRENIA;

EID: 71549157444     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.09.011     Document Type: Letter

References (14)

1. Bigos K.L., Pollock B.G., Coley K.C., Miller del D., Marder S.R., Aravagiri M., et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 48 2 (2008) 157-165
2. Chitturi S., and George J. Hepatotoxicity of commonly used drugs: nonsteroidal antiinflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 22 2 (2002) 169-183
3. Dumortier G., Cabaret W., Stamatiadis L., Saba G., Benadhira R., Rocamora J.F., et al. Hepatic tolerance of atypical antipsychotic drugs. Encephale 28 6 (2002) 542-551
4. Gossen D., de Suray J.M., Vandenhende F., Onkelinx C., and Gangji D. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci 4 2 (2002) E11
5. Hummer M., Kurz M., Kurtzhaler I., Oberbauer H., Miller C., and Fleischhacker W.W. Hepatotoxicity of clozapine. J Clin Pharmacol 17 (1997) 314-317
6. Jadallah K.A., Limauro D.L., and Colatrella A.M. Acute hepatocellular-cholestatic liver injury after olanzapine therapy. Ann Intern Med 138 4 (2003) 357-358
7. Kantrowitz J.T., and Citrome L. Olanzapine: review of safety 2008. Expert Opin Drug Saf 7 6 (2008) 761-769
8. Kumra S., Herion D., Jacobsen L.K., Briguglia C., and Grothe D. Case study: risperidone-induced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry 36 (1997) 1-5
9. Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., Roberts E.A., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30 2 (1981) 239-245
10. Ozcanli T., Erdogan A., Ozdemir S., Onen B., Ozmen M., Doksat K., et al. Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity. Prog Neuropsychopharmacol Biol Psychiatry 30 6 (2006) 1163-1166
11. Pollock B.G., Wylie M., Stack J.A., Sorisio D.A., Thompson D.S., Kirshner M.A., et al. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. J Clin Pharmacol 39 9 (1999) 936-940
12. Raz A., Bergman R., Eilam O., Yungerman T., and Hayek T. A case report of olanzapine-induced hypersensitivity syndrome. Am J Med Sci 321 2 (2001) 156-158
13. Szigethy E., Wiznitzer M., Branicky L.A., Maxwell K., and Findling R.L. Risperidone induced hepatotoxicity in children and adolescents? A chart review study. J Child Adolesc Psychopharmacol 9 (1999) 93-98
14. Tchernichovsky E., and Sirota P. Hepatotoxicity, leucopenia and neutropenia associated with olanzapine therapy. Int J Psychiatry Clin Pract 8 3 (2004) 173-177